Combination of lactate dehydrogenase and tumor mutational burden to predict clinical benefit of anti-CTLA-4 therapy in melanoma.

e15029Background: Tumor mutational burden (TMB) has been revealed to be associated with the clinical outcome of immune checkpoint blockade (ICB). Nevertheless, part of patients with relatively lowe...